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Introduction
Studies in the Polish population provided evidence that
four founder mutations in CHEK2 gene (1100delC, IVS2
+1G>A, I157T, del5395) are associated with increased
risk of cancers including breast, prostate, colon, kidney
and thyroid. The substantial variability in cancer pene-
trance in mutation carriers can probably be explained
by the influence of other genetic and/or environmental
factors. Selenium is an essential component of several
major metabolic pathways, including the antioxidant
defense system and the immune system. It has been
suggested that selenium and variations in selected sele-
noprotein genes may be risk factors for several cancer
types.
Aim
The aim of study was to check if Se concentration and
alteration in genes coding selenoproteins can be asso-
ciated with cancer risk in CHEK2 mutation carriers and
unselected patients.
Material and method
Biological samples (blood, serum, plasma) and clinical
information have been collected from 826 CHEK2 muta-
tion carriers - 670 healthy individuals and 156 cancer
cases - including breast, gastrointestinal tract (colon,
intestine, pancreas, stomach, gallbladder), respiratory
system (lung, larynx), prostate, kidney, ovarian and
others.
In the above groups cancer patients have been
matched to unaffected individuals in ratio 1:2 or 1:1.
The matching included CHEK2 mutation type, sex, year
of birth, smoking, number and location of cancer
among Iº relatives.
In all matched individuals Se concentration in serum/
plasma have been determined using ICP-MS and 4
SNPs in selenoprotein genes GPX1 (rs1050450), GPX4
(rs713041), TXNRD2 (rs1139793) and SEP15 (rs5845)
have been analyzed using Taqman probes.
To assess the cancer risk in relation to Se level and/or
studied alterations in selenoprotein genes the odds ratio
have been calculated using conditional logistic regres-
sion for matched groups. In tested groups the cancer
risk in relation to Se concentration was analyzed in
quartiles. All statistical analyses were performed using R
software.
Results
In the group of the matched CHEK2 carriers mean sele-
nium level was significantly lower in cancer patients than
in healthy controls: 73.2µg/l vs. 78.5µg/l (p=0.002). We
found that the cancer risk decreased with increased Se
concentration: individuals in IVth quartile (>86.28 µg/l)
in comparison to those in Ist quartile (<65.81µg/l) have
~2-times lower cancer risk (OR=0.46; p=0.01). We also
observed an association of CHEK2 associated cancer risk
depending on variants in selenoprotein genes. The data
analysis indicates modest association of rs5845 in SEP15
with breast, rs1050450 in GPX1 with prostate cancer and
rs713041 in GPX4 with lung/larynx cancer risk. Influence
of Se level on breast, prostate, lung and larynx cancer
risk may be dependent on variants in selenoprotein
genes.
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Conclusions
Our analyses clearly indicate that selenium can be a
modifier of cancer risk in CHEK2 mutation carriers.
The effect of selenium level in blood serum on cancer
risk may be dependent upon genotypes in selenoprotein
genes.
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